<HashMap><database>panorama</database><scores/><additional><omics_type>Proteomics</omics_type><submitter>Marketa Nezvedova</submitter><species>Homo Sapiens</species><full_dataset_link>https://panoramaweb.org/EOPVWs.url</full_dataset_link><submitter_email>marketa.nezvedova@recetox.muni.cz</submitter_email><submitter_affiliation>RECETOX, Faculty of Science, MUNI</submitter_affiliation><sample_protocol></sample_protocol><repository>PanoramaPublic</repository><data_protocol></data_protocol></additional><is_claimable>false</is_claimable><name>Comparing the Effects of Taurine and 3-Sulfopropanoic Acid, a Metabolite of Tramiprosate, on ApoE4 Pathological Aggregation: Implications for Alzheimer's Disease</name><description>Apolipoprotein E4 (ApoE4) is a major genetic risk factor for Alzheimer's disease. Its pathological aggregation can be mitigated by tramiprosate and its metabolite 3-sulfopropanoic acid, along with their impact on the transcription of genes, expression of proteins, and production of lipids. Taurine is a close chemical analogue of tramiprosate with an extra carbon atom, demonstrating protective effects against aging. Using an integrated approach involving static light scattering, hydrogen-deuterium exchange mass spectrometry, molecular dynamics, and studies of cerebral organoids, we evaluated the effects of 3-sulfopropanoic acid and taurine on ApoE4 aggregation, as well as their impact on organoid transcriptomics and proteomics. Our results reveal that taurine effectively inhibits ApoE4 aggregation, comparable to 3-sulfopropanoic acid, and ameliorates the pathophysiological phenotype of ApoE4 in cerebral organoids, aligning it more closely with the ApoE3 phenotype. These findings suggest that taurine may have potential as a therapeutic agent against Alzheimer's disease, particularly in ApoE4/E4 carriers.</description><dates><publication>Thu Jul 02 00:00:00 GMT+01:00 2026</publication></dates><accession>PXD059743</accession><cross_references><TAXONOMY>9606</TAXONOMY></cross_references></HashMap>